Arch Biopartners Closes Non-Brokered Private Placement

Executive Summary

• Arch Biopartners closed a non‑brokered private placement of 1,000,000 common shares at $0.60 each, generating gross proceeds of CAD $600,000.
• Proceeds will be used for general working capital and operating expenses not covered by existing human‑trial funding grants.
• The offering included a related‑party transaction (81,667 shares issued to an officer) that is exempt from valuation and minority‑shareholder approval requirements under MI 61‑101; all shares are subject to a four‑month‑plus‑one‑day hold period.

Key Details

• Offering size: 1,000,000 common shares at $0.60 per share.
• Gross proceeds: CAD $600,000.
• Closing date: April 2, 2026.
• Related‑party component: 81,667 shares issued to a company officer; transaction exempt from MI 61‑101 valuation/minority approval thresholds (≤25% of market cap).
• Hold period: All issued shares subject to a lock‑up of four months and one day from the closing date.
• Use of proceeds: General working capital and operating expenses not funded by existing human‑trial grants.
• Regulatory conditions: Closing contingent on receipt of applicable regulatory approvals, including final TSX Venture Exchange approval.
• Finder’s fees: None paid in connection with the offering.
• Share count post‑offering: 67,933,289 common shares outstanding.

Notable Quotes

(No executive quotes were included in the release.)